drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous chimeric antigen receptor T-cell product targeting GPRC5D; patient T cells are engineered ex vivo to express an anti-GPRC5D CAR (with CD3ζ signaling and costimulation) and infused intravenously to mediate antigen-specific cytotoxicity against GPRC5D-positive myeloma cells. Dose: 3.0–6.0×10^6 CAR+ T cells/kg.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered ex vivo to express a chimeric antigen receptor targeting GPRC5D with CD3ζ signaling and costimulatory domains; upon infusion, CAR-T cells bind GPRC5D on myeloma cells, become activated, proliferate, release cytokines, and mediate antigen-specific cytotoxicity (perforin/granzyme) to eliminate GPRC5D-positive malignant plasma cells.
drug_name
Anti-GPRC5D CAR-T Cells Injection
nct_id_drug_ref
NCT05749133